



MATERIAL SAFETY DATA SHEET

Product Name: Lidocaine Hydrochloride Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address Hospira, Inc.
275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone Hospira, Inc. CHEMTREC: 800 424-9300
224 212-2055

Product Name Lidocaine Hydrochloride Injection/Topical Solution, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Lidocaine Hydrochloride
Chemical Formula C₁₄H₂₃ClN₂O

| Component | Approximate Percent by Weight | CAS Number | RTECS Number |
|-------------------------|-------------------------------|------------|--------------|
| Lidocaine Hydrochloride | 0.05 – 0.5 | 73-78-9 | AN7600000 |
| Water | 99 | 7732-18-5 | ZC0110000 |

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material is used to numb body tissues. Lidocaine is toxic by ingestion and besides its numbing effects, can affect the central nervous system, respiratory system, and cardiovascular system.

Occupational Exposure Potential Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms No signs or symptoms from occupational exposure are known. Clinical data suggest the following: numbness, lightheadedness, transient deafness, drowsiness, dizziness, restlessness, breathing difficulty, anxiety, vomiting, tremor, stupor, convulsions, respiratory distress, decreased blood pressure, slow heart rate.

Medical Conditions Aggravated by Exposure Hypersensitivity to the material and/or similar materials. Pre-existing ailments in the following organs: eyes, central nervous system, cardiovascular system.

Product Name: Lidocaine Hydrochloride Injection, USP

4. FIRST AID MEASURES

| | |
|----------------------|---|
| Eye Contact: | Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |
| Skin Contact: | Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |
| Inhalation: | Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary. |
| Ingestion: | Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary. |

5. FIRE FIGHTING MEASURES

| | |
|---|--|
| Flammability: | Non-flammable. |
| Fire & Explosion Hazard: | None |
| Extinguishing Media: | Use extinguishing media appropriate for primary cause of fire. |
| Special Fire Fighting Procedures | No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus. |

6. ACCIDENTAL RELEASE MEASURES

| | |
|-----------------------------------|---|
| Spill Cleanup and Disposal | Absorb with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations. |
|-----------------------------------|---|

7. HANDLING AND STORAGE

| | |
|----------------------------|---|
| Handling | No special handling required. |
| Storage | No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F). |
| Special Precautions | Protect from freezing and extreme heat. |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

| Component | Exposure limits | | |
|-------------------------|---------------------------|---------------------------|---|
| | OSHA-PEL | ACGIH-TLV | Hospira EEL |
| Lidocaine Hydrochloride | 8 hr TWA: Not Established | 8 hr TWA: Not Established | 8 hr TWA: 500 mcg/m ³ STEL: 5 mg/m ³ |

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Lidocaine Hydrochloride Injection, USP

| | |
|-------------------------------|---|
| Respiratory Protection | Respiratory protection is not needed during normal product use. |
| Skin Protection | If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice. |
| Eye Protection | Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist. |
| Engineering Controls | Engineering controls are not needed during normal product use conditions. |

9. PHYSICAL/CHEMICAL PROPERTIES

| | |
|----------------------------------|---|
| Appearance/Physical State | Clear liquid |
| Odor | Not Applicable |
| Boiling Point | Approximately that of water (100 °C, 212 °F). |
| Freezing Point | Approximately that of water (0 °C, 32 °F). |
| Vapor Pressure | Not Applicable |
| Vapor Density (Air=1) | Not Applicable |
| Evaporation Rate | Not Applicable |
| Bulk Density | Not Determined |
| Specific Gravity | Approximately that of water (1.0) |
| Solubility | Aqueous solution |
| pH | 3.0 – 7.0 |

10. STABILITY AND REACTIVITY

| | |
|---|---|
| Chemical Stability | Stable under standard use and storage conditions. |
| Incompatibilities | Not Determined |
| Hazardous Decomposition Products | Toxic fumes of nitrogen oxides and HCl |
| Hazardous Polymerization | Not Determined. |

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

| Ingredient(s) | Percent | Test Type | Value | Units | Species |
|-------------------------|---------|-----------|------------|-------|--------------|
| Lidocaine Hydrochloride | 100 | LD50 | 317 220 | mg/kg | Rats Mice |

LD50 is the dosage producing 50% mortality.

Product contains between approximately 0.05 – 0.5% Lidocaine Hydrochloride.

| | |
|-----------------------------|---|
| Mutagenicity | Not Determined |
| Target Organ Effects | In clinical use target organ effects include central nervous system, cardiovascular system. |

Product Name: Lidocaine Hydrochloride Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not Available

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Not Regulated
CERCLA Status Not Regulated
SARA Status Not Regulated
RCRA Status Not Regulated
PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act
 CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
 SARA Superfund Amendments and Reauthorization Act
 RCRA US EPA, Resource Conservation and Recovery Act
 Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology
Date Prepared September 15, 2005
Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.